Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
This phase I, nonrandomized, open-label study evaluated the safety and efficacy of combining the histone deacetylase inhibitor vorinostat with either the mTOR inhibitor sirolimus (V+S) or everolimus (V+E) in 40 patients with relapsed/refractory Hodgkin lymphoma who had undergone a median of five prior therapies, including brentuximab and stem cell transplantation.
June 26, 2025
No Comments